Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto
About this trial
The goal of this retrospective observational study is to learn about the efficacy of ponatinib in Philadelphia-positive ALL (Ph+ ALL) patients in a real-world setting. The main goal of the study is to assess the rate of complete molecular response (CMR) induced by ponatinib in patients treated under the regulations of Law 648/96, outside clinical trials.
Patients who were treated with ponatinib as part of their regular medical care and completed the follow-up period will be included in the study.
Eligibility criteria
Qualifiers
Patient is > 18 years old;
Patient was treated in first-line with ponatinib monotherapy or in association with chemotherapy or immunotherapy;
Patient received ponatinib under the regulations of Law 648/96;
- Patient is alive and have at least 18 months of retrospective observation available from the start of ponatinib treatment, OR
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
103 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov